Skip to main content

Before the end-of-year cheer is exchanged for 2023’s hecticness, MT Group would like to take a minute to thank you, our customers, for your partnership through 2022. Our goal has been and always will be to support researchers with the highest quality biospecimen-focused CRO services. 2022 was a great year for us, with broadened customer relationships as well as the expansion of our immuno-oncology, fresh tissue, autoimmune, and liquid biopsy programs. We look forward to exploring new collaboration opportunities with you in 2023!

New Capabilities
We brought on 30 new sites in 2022, broadening our reach in the following areas:
* Cardiological diseases: hypertension, myocardial infarction, and hypercholesterolemia
* Autoimmune diseases: inflammatory bowel disease, diabetes, lupus, and rheumatoid arthritis
* Dermatological disorders: atopic dermatitis and psoriasis
* Pulmonary diseases: asthma, chronic obstructive pulmonary disorder, and pulmonary hypertension
* Gastrointestinal diseases: NASH, irritable bowel syndrome, gastritis, Barrett’s esophagus, and gastric ulcers
* Infectious diseases: hepatitis, influenza, and COVID-19
* Latin America, Europe, and Asia
* Large academic centers and biobanks

Select Studies
We conducted several hundred biospecimen studies last year, including:
* 2,000 subject multi-cancer with matched controls
* NASH biopsy tissue and blood
* High risk / pre-cancer subjects collected at colonoscopy, mammogram, and CT scan
* Healthy Asian-Americans and African-Americans with a full medical assessment prior to blood draw
* Fresh lung cancer blood collected on-therapy and post-therapy
* Post neoadjuvant IO and chemo resection tissue
* Fresh skin and blood from healthy subjects and those with dermatological autoimmune diseases
* Subjects collected post-COVID infection, influenza infection, and immunization

MT Group wants to thank you again for making 2022 such a success. We wish you the best for 2023!